CTSH is a gene involved in cellular processes relevant to neurodegeneration.
Full Name: Cathepsin H
Chromosome: 15q25.1
NCBI Gene ID: 1515
OMIM ID: 601009
Ensembl ID: ENSG00000103852
UniProt ID: P09668
CTSH encodes cathepsin H, a lysosomal cysteine protease belonging to the papain family. This enzyme has been implicated in Alzheimer disease (AD) through genome-wide association studies (GWAS), with elevated expression observed in AD brains [1][2]. CTSH plays important roles in protein degradation, antigen processing, and APP metabolism, making it a gene of interest in neurodegenerative disease research.
Cathepsin H is a cysteine protease with unique characteristics among lysosomal cathepsins:
- Endopeptidase activity: Cleaves peptide bonds within protein substrates
- Exopeptidase activity: Possesses aminopeptidase activity (monopeptidyl dipeptidase)
- Optimal pH: 5.5-6.5 in lysosomes
- Structure: Single-chain glycoprotein (~253 amino acids)
- Activation: Processed from pro-cathepsin H (37 kDa) to mature form (27 kDa)
Cathepsin H degrades various substrates including:
- Protein degradation: Lysosomal protein turnover
- Antigen processing: MHC class II antigen presentation
- Hormone processing: Activation of peptide hormones
- Wound healing: Extracellular matrix remodeling
- Cell signaling: Regulation of growth factors
CTSH has been identified as an AD risk gene through GWAS [1][2]. Key associations include:
- Genetic association: Common variants in CTSH locus associated with increased AD risk
- Gene expression: Elevated CTSH expression in AD brain, particularly in microglia
- Amyloid metabolism: May influence APP processing and Aβ generation
- Neuroinflammation: Upregulated in response to amyloid deposition
- Elevated CTSH in substantia nigra of PD patients
- May contribute to alpha-synuclein degradation
- Potential role in Lewy body formation
- Lewy Body Dementia: Increased cathepsin H in affected brain regions
- Frontotemporal Dementia: Altered lysosomal protease expression
- Amyotrophic Lateral Sclerosis: Dysregulated in motor neurons
CTSH is expressed in various tissues:
- Brain: Neurons, microglia, astrocytes
- Immune system: Macrophages, dendritic cells
- Liver: Hepatocytes
- Kidney: Tubular cells
- Lung: Alveolar macrophages
In the brain, CTSH is particularly expressed in:
- Microglial cells (brain macrophages)
- Certain neuronal populations
- Vascular endothelial cells
CTSH represents a potential therapeutic target:
- Inhibitor development: Selective CTSH inhibitors could modulate amyloid metabolism
- Activity modulators: Compounds enhancing CTSH activity may improve protein clearance
- Blood-brain barrier considerations: CNS-penetrant compounds needed
- CTSH levels in cerebrospinal fluid (CSF) may serve as a biomarker
- Microglial activation marker
- Potential for disease progression tracking
¶ Interactions and Pathway Context
| Pathway |
Role |
| Lysosomal Degradation |
Protein turnover in neurons |
| APP Processing |
Amyloid metabolism |
| Autophagy |
Protein aggregate clearance |
| Neuroinflammation |
Microglial activation |
| MHC Class II |
Antigen presentation |
Ctsh-deficient mice show:
- Accumulation of lysosomal storage material
- Altered immune function
- Deficits in antigen processing
- No severe neurodegeneration under normal conditions
- CTSH overexpression in mouse brain leads to altered amyloid metabolism
- Modulates Aβ plaque formation in APP transgenic mice
- CTSH variants are not routinely tested clinically
- Associated risk variants are common in population
- Research use for understanding disease mechanisms
- CSF cathepsin H levels under investigation
- Potential marker for microglial activation
Cathepsin H is conserved across species:
- Humans: CTSH gene
- Mice: Ctsh gene
- Zebrafish: ctsh genes
- Drosophila: Cathepsin L-like proteases